This report is not a personal recommendation and does not take into account your personal circumstances or appetite for risk.
The below stocks have been identified as having potential to register bigger than normal share price moves (up or down) today based on the news cited
AstraZeneca (AZN) - The drugmaker has announced that phase 3 trials for its asthma drug Tralokinumab have disappointed, failing to produce significant results in a range of trials to treat severe asthma.
Indivior (INDV) - The US FDA has recommended the approval of its drug for opioid addiction treatment.
Next (NXT) - The high street retailer has announced a return to quarterly sales growth in Q3, however warned that conditions remain challenging while cutting its sales guidance in the run-up to the crucial Christmas period. While full prices sales increased 1.3% YoY, the company is still running a sales decline for the full year.
Royal Dutch Shell (RDSb) - Ahead of its Q3 results tomorrow, the Oil giant has announced it has completed the sale of a package of North Sea assets to Chrysoar for a reported $3.8bn.
Standard Chartered (STAN) - The Asian lender will release its Q3 results at 8:30am this morning.
(Sources: Company Newswires, Bloomberg, FT, Reuters, Wall Street Journal)
For more information on any of these individual news items, call into the trading floor
| Stock | Code | Close | High | Low |
| BP | BP/ | 1.7% | 4.1% | 1.2% |
| RYANAIR HOLDINGS | RYA | 6.4% | 7.6% | 3.1% |
| WEIR GROUP | WEIR | -6.8% | -4.6% | -9.1% |
| WPP | WPP | 3.0% | 3.6% | -2.7% |
This research is produced by Accendo Markets Limited. Research produced and disseminated by Accendo Markets is classified as non-independent research, and is therefore a marketing communication. This investment research has not been prepared in accordance with legal requirements designed to promote its independence and it is not subject to the prohibition on dealing ahead of the dissemination of investment research. This research does not constitute a personal recommendation or offer to enter into a transaction or an investment, and is produced and distributed for information purposes only.
Accendo Markets considers opinions and information contained within the research to be valid when published, and gives no warranty as to the investments referred to in this material. The income from the investments referred to may go down as well as up, and investors may realise losses on investments. The past performance of a particular investment is not necessarily a guide to its future performance. Prepared by Michael van Dulken, Head of Research